Analysts at Janney Montgomery Scott initiated coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued on Friday, June 2nd. The firm set a “sell” rating and a $67.00 price target on the biopharmaceutical company’s stock. Janney Montgomery Scott’s target price points to a potential downside of 20.73% from the company’s previous close.

Several other brokerages have also recently weighed in on ALNY. Vetr cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. Piper Jaffray Companies set a $118.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Chardan Capital lowered their price target on Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, May 15th. Ladenburg Thalmann Financial Services set a $80.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. Finally, ValuEngine lowered Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 27th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $71.82.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Shares of Alnylam Pharmaceuticals (ALNY) opened at 84.52 on Friday. The firm’s market capitalization is $7.28 billion. The stock’s 50 day moving average price is $67.47 and its 200-day moving average price is $51.64. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $84.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. During the same quarter in the previous year, the company posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.30) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/22/alnylam-pharmaceuticals-inc-alny-earns-sell-rating-from-analysts-at-janney-montgomery-scott-updated-updated.html.

In other news, EVP Akshay Vaishnaw sold 11,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total value of $825,000.00. Following the sale, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at $1,597,275. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sanofi bought 297,501 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 31st. The stock was purchased at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 64,125 shares of company stock worth $4,325,000. Insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $4,632,000. Aviva PLC raised its position in Alnylam Pharmaceuticals by 6.2% in the fourth quarter. Aviva PLC now owns 48,022 shares of the biopharmaceutical company’s stock valued at $1,797,000 after buying an additional 2,793 shares in the last quarter. Hemenway Trust Co LLC raised its position in Alnylam Pharmaceuticals by 25.2% in the fourth quarter. Hemenway Trust Co LLC now owns 16,773 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 3,373 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. Finally, State Street Corp raised its position in shares of Alnylam Pharmaceuticals by 1.2% in the fourth quarter. State Street Corp now owns 2,361,998 shares of the biopharmaceutical company’s stock valued at $88,430,000 after buying an additional 28,822 shares during the period. Institutional investors own 90.04% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.